Elif A Oral, MD

Elif Oral, MD

Specialty: Endocrinology, Internal Medicine
Title: Professor
4.9/5
See All Ratings

To request an appointment call

866-266-5221
Elif A Oral, MD
Elif Oral, MD
Endocrinology
  • About
  • Areas of Practice
  • Expertise
  • Locations
  • Insurance
  • Education & Training
  • Research Overview
  • Links
  • Manage Your Profile

  • About

    Dr. Elif Oral is a professor in the Division of Metabolism, Endocrinology and Diabetes (MEND) at the University of Michigan. She completed her medical education in her home country of Turkey at the University of Istanbul. In 1996, she completed her residency in Internal Medicine at Sinai Hospital Detroit (Michigan). She then completed a fellowship in Endocrinology, Metabolism and Diabetes at the National Institute of Health, where she also chose to stay as a Senior Fellow under the mentorship of Drs SimeonTaylor and Phillip Gorden in in the Diabetes Branch of NIDDK.

    Since joining the University of Michigan in 2002 as an Assistant Professor of Medicine, along with her regular faculty responsibilities, Dr. Oral also completed a Masters of Science Degree in Clinical Research Design and Biostatistics at the School of Public Health. Her clinical interests are in insulin resistance, obesity, lipid disorders, and diabetes.

    Dr Oral's research focuses on the importance of adipocytes in human metabolism and adipocyte hormones such as leptin. She is best known for her work showing the remarkable efficacy of leptin in rare lipodystrophy syndromes. Metreleptin received approval by the FDA (2014) and EMA (2016) as a treatment for lipodystrophy owing to a large part to her original vision and work. These studies provided the basis for her current work with three big goals: identification of novel metabolic diseases, discovery of new disease mechanisms and finding treatments for patients afflicted with these disorders.

    In addition to her roles as physician, educator, and researcher, Dr Oral is also the director of two programs at MEND: Atypical Diabetes Program and Obesity and Metabolic Disorders Program. She directed the Post-Bariatric Surgery Care Program from 2012 to 2021 and continues to conduct research on the cohort of patients who had bariatric surgery performed in the Michigan Bariatric Surgery program.

    Areas of Practice

    Atypical diabetes , rare endocrine disorders, undiagnosed metabolic disorders (mystery cases), genetic and acquired forms lipodystrophy and/or obesity, rare causes of Type 2 or Type 1 diabetes (atypical diabetes), lipid disorders (common or rare).

    Locations

    • Metabolism, Endocrinology & Diabetes Clinic | Domino's Farms 24 Frank Lloyd Wright Dr Ste 1300
      Lobby C
      Ann Arbor, MI 48105-9484
      Get Directions
    • Cardiovascular Medicine Clinic | Domino's Farms 24 Frank Lloyd Wright Dr. Ste 1300
      Lobby A
      Ann Arbor, MI 48106-0363
      Get Directions

    Insurance Accepted

    University of Michigan Health participates with most health insurance plans.

    See our insurance details

    Education & Training

    Medical School or Training

    Istanbul Universitesi, 1992

    Residency

    Sinai-Grace Hospital of Detroit - DMC, Rotating Internal Medicine, 1996

    Fellowships

    Inter-Institute NIH Training Program in Endocrinology, IM Endocrinology, Metabolism & Diabetes, 1999

    Board Certifications

    Endocrinology, Diabetes & Metabolism

    Research Overview

    Lipodystrophy, obesity, lipid metabolism, physiological roles of leptin, nonalcoholic steatohepatitis

    Links

    Division of Metabolism, Endocrinology & Diabetes

    Featured News & Stories

    woman hugging patient in exam room
    Health Lab

    A unique patient case inspiring research

    Mallory Mattison serves as the inspiration behind critical medical research that’s supporting other patients like her with lipodystrophy syndromes
    group of people smiling and posing with white hat
    Health Lab

    Researchers uncover why a rare disease resulting in abnormal fat loss can also lead to diabetes

    With help of patients with FPLD2, a research team has finally found some answers to why familial partial lipodystrophy can lead to diabetes and metabolic disease.